“Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S45, https://doi.org/10.25251/skin.2.supp.45.